mRNA 백신에서 지질나노입자(LNP) 대신 바이러스 유사입자(VLP)를 사용하는 방법.

[루시엘]

https://www.facebook.com/share/p/1GpBucrVqr/
 

Jay Wilson

 
 
 
----------------------------------------------------------------------------------------
 
제가 완전하게 열람한 중요한 문헌입니다. 꼭 읽어보시길 바랍니다.
끝까지 읽으세요!! 이 기술은 바이러스 유사 입자를 활용합니다!!

"마이크로RNA 바이오센서: 기존 및 상용 기술 간의 기회와 과제"

PII:S0956-5663(17)30542-0
참고문헌:BIOS9917
http://dx.doi.org/10.1016/j.bios.2017.08.007

---

논문 요약

마이크로RNA(miRNA)는 우리 몸의 유전자 발현을 조절하는 아주 작은 "분자 스위치"라고 생각하면 됩니다. 크기는 작지만, 세포 성장부터 뇌 기능에 이르기까지 우리 몸이 정상적으로 기능하는 데 매우 중요한 역할을 합니다. 이 스위치의 균형이 깨지면 암, 심장병, 자가면역 질환과 같은 심각한 문제를 일으킬 수 있습니다.

이러한 이유로 과학자들은 체내 miRNA를 측정하고자 합니다. 정확하게 측정할 수 있다면 miRNA는 질병의 "경고 신호" 역할을 하여 의사가 암이나 다른 질병을 증상이 나타나기 전에도 조기에 발견할 수 있도록 도와줄 수 있습니다.

그렇다면 miRNA는 어떻게 검출할까요?

기존에는 PCR 검사, 노던 블롯, 마이크로어레이와 같은 방법을 사용해 왔습니다. 이러한 방법들은 정확하지만 다음과 같은 단점이 있습니다.

반응 속도가 느리고 비용이 많이 듭니다.

대형 실험 장비가 필요한 경우가 많습니다.

진료실에서 신속하게 검사하기에는 적합하지 않습니다.

새로운 접근 방식: 바이오센서

바이오센서는 miRNA를 "감지"할 수 있는 아주 작은 장치입니다. 바이오센서는 다음과 같은 구성 요소로 이루어져 있습니다.

1. miRNA를 포획하는 요소 (miRNA를 포획하는 벨크로와 같은 역할을 함)

2. miRNA 포획을 측정 가능한 신호로 변환하는 센서 (빛이 켜지거나 미세한 전류가 흐르는 것과 같은 신호)

이러한 센서는 다양한 방식으로 제작될 수 있습니다.

전기화학 센서: miRNA가 결합할 때 발생하는 미세한 전기 신호를 측정합니다.

광학 센서: 빛, 형광 또는 빛을 내거나 색이 변하는 특수 나노 입자를 사용합니다.

종이 기반 또는 휴대용 센서: 저렴하고 일회용이며, 임신 테스트기와 유사합니다.

나노기술(금 나노 입자 또는 그래핀과 같은 소재 사용) 덕분에 이러한 바이오센서는 혈액이나 타액에서 극소량의 miRNA 분자까지 검출할 수 있을 정도로 민감해지고 있습니다.

이것이 중요한 이유

비침습적 검사: 의사는 고통스러운 생검 대신 간단한 혈액 또는 타액 샘플만으로 암을 검사할 수 있습니다.

조기 발견: 증상이 나타나기 훨씬 전에 질병을 발견할 수 있습니다.

맞춤형 의료: 치료 효과를 실시간으로 추적할 수 있습니다.

남은 과제

모든 연구실이나 병원에서 동일한 결과를 얻을 수 있도록 이러한 센서의 표준화가 필요합니다.

병원에서 널리 도입하기 위해서는 저렴하고 신뢰할 수 있으며 사용하기 쉬운 센서를 개발해야 합니다.

여러 miRNA를 동시에 검출하고 위양성을 방지하기 위해서는 더 많은 연구가 필요합니다.

---

패러다임의 변화

이 논문은 우리가 큰 변화의 문턱에 서 있다고 말합니다. 미래에는 샘플을 대형 연구소에 보내고 며칠씩 기다리는 대신, 주머니 크기의 센서로 몇 분 만에 암 관련 miRNA를 검출할 수 있을 것입니다. 마치 당뇨병 혈당 측정기처럼 말이죠.

---

mRNA 백신 vs. miRNA 바이오센서

1. mRNA 백신 (예: 코로나19 백신)

이 백신은 세포가 단백질을 만드는 데 사용하는 주형인 메신저 RNA(mRNA)를 이용합니다.

백신에서 mRNA는 무해한 바이러스 단백질(예: 코로나19 스파이크 단백질)을 암호화합니다. 그러면 면역 체계는 이를 인식하는 법을 학습합니다.

목적: 면역 체계 훈련

2. 마이크로RNA(miRNA)

miRNA는 매우 짧은 비코딩 RNA(약 18~25개 뉴클레오티드 길이)입니다.

단백질을 생성하지 않고, 마치 "조광 스위치"처럼 유전자 활동을 조절합니다.

목적: 신체 내 유전자의 활성을 조절합니다.
 
따라서 mRNA 백신과 miRNA는 둘 다 RNA 분자이지만, 목적이 다른 별개의 도구입니다.

---

공통점

진단: 제가 업로드한 논문은 혈액이나 타액에서 비정상적인 miRNA 패턴을 감지하는 miRNA 바이오센서에 관한 것입니다. 예를 들어, 특정 miRNA는 암이나 감염에서 "균형이 깨지므로" 이를 측정하는 것은 조기 경보 시스템 역할을 할 수 있습니다.

치료: 연구자들은 miRNA 기반 치료법을 실험하고 있는데, 유해한 miRNA를 차단하거나("안타고미어") 부족한 유익한 miRNA를 보충하는 방식입니다. 이는 mRNA 백신이 세포에 RNA를 전달하는 방식과 유사하지만, 면역 체계를 훈련시키는 대신 유전자 조절을 재설정하는 것을 목표로 합니다.

기술적 중복: COVID-19 mRNA 백신에 사용된 전달 방법인 지질 나노입자(LNP)는 miRNA 치료법에도 연구되고 있습니다. 이는 두 분야를 직접적으로 연결하는 고리입니다.

---

협력

mRNA 백신 = 단백질을 만드는 데 필요한 정보를 전달합니다.

miRNA 바이오센서/치료법은 우리 몸의 유전자 "스위치"를 감지하거나 조절하는 것입니다.

서로 다른 역할을 하지만, 동일한 RNA 기반 도구와 전달 기술(나노입자, 운반체)을 공유하는 경우가 많습니다.

제가 게시한 논문에서는 miRNA 감지 및 치료 맥락에서 바이러스 유사 입자(VLP)를 다루고 있습니다. 이에 대해 설명하고 백신과의 연관성을 살펴보겠습니다.

---

논문에 언급된 바이러스 유사 입자(VLP)

해당 리뷰에서는 miRNA 치료제가 바이러스 기반 구조물을 전달 방법 중 하나로 사용할 수 있다고 언급합니다.

특히, 유해한 miRNA(온코미르)를 차단할 때 연구자들은 다음과 같은 두 가지 방법을 사용할 수 있습니다.

1. 직접적인 화학적 접근법(안타고미르, LNA 등)

2. 또는 간접적인 바이러스 유사 시스템(바이러스를 모방하지만 질병을 유발하지 않는 유전자 조작 입자)을 사용하여 항 miRNA 서열을 세포 내로 전달하는 방법

이러한 VLP는 마치 운반 드론처럼 유전 물질을 세포 안으로 효율적으로 몰래 침투시키는 역할을 하며, 실제 바이러스와 유사한 방식으로 작동합니다.

---

RNA 백신과의 연관성

mRNA 백신(예: 화이자/모더나의 COVID-19 백신)은 VLP를 사용하지 않고 지질 나노입자(LNP)를 사용합니다.

하지만 초기 백신 연구에서는 VLP를 항원 전달에 사용했으며, 일부 실험적인 RNA/miRNA 치료법에서는 유전자 조절 물질 전달을 위해 VLP를 탐색하고 있습니다.

두 경우 모두 원리는 동일합니다. 바이러스와 유사한 외피가 RNA를 세포 안으로 안전하게 전달하는 자연적인 능력을 활용하는 것입니다.

---

VLP가 이 분야에서 중요한 이유

생체 센서/치료제 분야에서 이 논문은 VLP가 miRNA 차단제 또는 대체제를 특정 조직에 전달하는 유망한 방법임을 지적합니다.

백신 분야에서 VLP(바이러스 유사 입자)는 이미 널리 사용되고 있습니다. 예를 들어, HPV 백신(가다실 등)은 HPV 외피 단백질의 바이러스 유사 입자를 이용합니다.

이는 두 기술이 서로 겹치는 부분이 있음을 의미합니다.

VLP는 백신 항원을 전달할 수 있습니다.

VLP는 RNA/miRNA 치료제를 전달할 수 있습니다.

생체 센서는 miRNA "특징"을 추적하여 면역 반응이나 치료 효과를 모니터링할 수 있습니다.

---

✅요약하자면,
본 논문은 바이러스 유사 입자를 miRNA 치료제 전달 도구 중 하나로 강조합니다. VLP는 이미 HPV, B형 간염 백신 등 백신 플랫폼으로 검증되었기 때문에 백신 분야와도 잘 어울립니다. 또한 RNA와 miRNA 기술이 면역 체계 훈련(백신) 또는 유전자 조절 재프로그래밍(miRNA 치료제)이라는 공통적인 전달 전략을 공유한다는 것을 보여줍니다.
 
------------------
 
This is an Important piece of literature that I have gained full access too. This is a must read.
READ UNTIL THE END!! THIS TECHNOLOGY UTILIZES VIRUS LIKE PARTICLES!!
 
"microRNA biosensors: opportunities and challenges among conventional and commercially available techniques"
 
PII:S0956-5663(17)30542-0
Reference:BIOS9917
http://dx.doi.org/10.1016/j.bios.2017.08.007
 
---
 
Article Summary
 
Think of microRNAs (miRNAs) as tiny “molecular switches” that help control how our genes are turned on or off. Even though they’re small, they play a huge role in keeping our bodies running properly — from cell growth to brain function. When these switches get out of balance, they can cause serious problems like cancer, heart disease, or autoimmune disorders.
 
Because of this, scientists want to measure miRNAs in the body. If we can do that accurately, miRNAs could act like “warning lights” for disease — letting doctors spot cancer and other illnesses very early, sometimes before symptoms even appear.
 
How do we detect them?
 
Traditionally, labs have used methods like PCR tests, Northern blots, and microarrays. These are accurate but:
 
They’re slow and expensive.
 
They often require large lab equipment.
 
They’re not practical for quick tests in a doctor’s office.
 
The new approach: biosensors
 
A biosensor is like a tiny device that can “sniff out” miRNAs. It works by having:
 
1. A capture element (like Velcro for the miRNA).
 
2. A sensor that turns that capture event into a measurable signal (like a light turning on or a small electric current).
 
These sensors can be made in different ways:
 
Electrochemical sensors: measure tiny electrical signals when miRNAs bind.
 
Optical sensors: use light, fluorescence, or special nanoparticles that glow or change color.
 
Paper-based or portable sensors: cheap and disposable, kind of like a pregnancy test strip.
 
Thanks to nanotechnology (using materials like gold nanoparticles or graphene), these biosensors are becoming so sensitive they can detect even a handful of miRNA molecules in blood or saliva.
 
Why this matters
 
Non-invasive tests: Doctors could check for cancer with a simple blood or saliva sample instead of painful biopsies.
 
Early detection: Catch diseases long before symptoms appear.
 
Personalized medicine: Track how well a treatment is working in real time.
 
Challenges left
 
These sensors still need to be standardized so every lab or clinic gets the same results.
 
They need to be made cheap, reliable, and easy to use before hospitals adopt them widely.
 
More work is needed to detect multiple miRNAs at once and to avoid false positives.
 
---
 
Shifting the paradigm
 
The paper says we’re on the verge of a big shift. In the future, instead of sending samples to a big lab and waiting days, you might have a pocket-sized sensor that can detect cancer-related miRNAs in minutes — almost like a blood-sugar meter for diabetes.
 
---
 
mRNA Vaccines vs. miRNA Biosensors
 
1. mRNA Vaccines (like COVID-19 vaccines)
 
These use messenger RNA (mRNA), which is a template your cells read to make proteins.
 
In vaccines, the mRNA encodes a harmless version of a virus protein (like the COVID-19 spike protein). Your immune system then learns to recognize it.
 
Purpose: train the immune system.
 
2. microRNAs (miRNAs)
 
These are very short, non-coding RNAs (about 18–25 nucleotides long).
 
They don’t make proteins. Instead, they act like “dimmer switches,” turning gene activity up or down.
 
Purpose: regulate your body’s own genes.
 
So, while both are RNA molecules, mRNA vaccines and miRNAs are different tools with different purposes.
 
---
 
Where they connect
 
Diagnostics: The paper I uploaded is about miRNA biosensors, which detect abnormal miRNA patterns in blood or saliva. For example, certain miRNAs go “out of balance” in cancers or infections, so measuring them could act like an early warning system.
 
Therapeutics: Researchers are experimenting with miRNA-based therapies — either blocking harmful miRNAs (“antagomirs”) or replacing beneficial ones that are missing. This is more similar to how mRNA vaccines deliver RNA into cells, but instead of training the immune system, the goal is to reset gene regulation.
 
Technology overlap: The delivery methods — lipid nanoparticles (LNPs) — used in COVID-19 mRNA vaccines are also being studied for miRNA therapies. That’s a direct link between the two fields.
 
---
 
Working Together
 
mRNA vaccines = deliver instructions to make a protein.
 
miRNA biosensors/therapies = detect or regulate your body’s own gene “switches.”
 
They don’t serve the same role, but they share the same RNA-based toolkit and often the same delivery technology (nanoparticles, carriers).
 
The paper I posted does touch on virus-like particles (VLPs) in the context of miRNA detection and therapy . Let me explain that and then connect it to the vaccine side:
 
---
 
Virus-Like Particles (VLPs) in the Paper
 
The review mentions that miRNA therapeutics can use virus-based constructs as one delivery method.
 
Specifically, when blocking harmful miRNAs (called oncomiRs), researchers can either:
 
1. Use direct chemical approaches (like antagomirs, locked nucleic acids).
 
2. Or use indirect virus-like systems — engineered particles that mimic viruses but don’t cause disease, carrying anti-miRNA sequences into cells.
 
These VLPs work like delivery drones, sneaking genetic material into cells efficiently, just as real viruses do.
 
---
 
Connection to RNA Vaccines
 
mRNA vaccines (e.g., Pfizer/Moderna COVID-19) don’t use VLPs — they rely on lipid nanoparticles (LNPs) instead.
 
But in earlier vaccine research, VLPs have been used to deliver antigens, and in some experimental RNA/miRNA therapies, VLPs are explored for gene regulation delivery.
 
In both cases, the principle is the same: harness the natural ability of virus-like shells to get RNA safely inside cells.
 
---
 
Why VLPs are Relevant Here
 
In the biosensor/therapeutics context, the paper points out VLPs as a promising method to deliver miRNA blockers or replacements into specific tissues.
 
In the vaccine world, VLPs are already well established — for example, HPV vaccines (like Gardasil) use virus-like particles of the HPV shell protein.
 
This means the technologies overlap:
 
VLPs can deliver vaccine antigens.
 
VLPs can deliver RNA/miRNA therapies.
 
Biosensors can then track miRNA “signatures” to monitor immune response or treatment success.
 
---
 
✅So in summary:
The paper highlights virus-like particles as one of the delivery tools for miRNA therapies. This concept ties neatly into vaccines, since VLPs are already a proven vaccine platform (HPV, hepatitis B). It shows how RNA and miRNA technologies share common delivery strategies — whether the goal is to train the immune system (vaccines) or reprogram gene regulation (miRNA therapeutics).